A clinical trial aimed to evaluate the efficacy, safety and pharmacokinetics of oral APOL1 inhibitor (VX-147) is ongoing in patients with FSGS and APOL1 G1/G1, G2/G2 or G1/G2 genotypes (NCT04340362, Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis) [53]. Here, APOL1 is linked to focal segmental glomerulosclerosis.